Donald Trump signed an executive order on April 18, 2026, to accelerate federal research into the medical use of psychedelics [1, 2].
This move signals a potential shift in U.S. federal policy regarding controlled substances, prioritizing scientific discovery over traditional prohibition to address a growing mental-health crisis.
The executive order specifically targets the study of substances such as LSD, psilocybin, and ibogaine [1, 2]. By streamlining the research process, the federal government aims to determine if these compounds can serve as effective treatments for various mental-health conditions [1, 2].
Federal agencies are now tasked with speeding up the scientific investigation of these psychedelics [1, 2]. The initiative seeks to remove bureaucratic hurdles that have historically slowed the clinical study of Schedule I substances, a category that typically includes drugs with a high potential for abuse and no currently accepted medical use.
While the order focuses on research rather than widespread legalization, it opens a door for the medical community to explore alternative therapies [2]. The focus remains on the therapeutic potential of these substances to treat patients who may not respond to traditional psychiatric medications [1, 2].
This federal push follows a trend of emerging interest in psychedelic-assisted therapy across several U.S. states. By utilizing an executive order, the administration bypasses the slower legislative process of Congress to initiate these studies immediately [1, 2].
“Donald Trump signed an executive order on April 18, 2026, to accelerate federal research into the medical use of psychedelics.”
This order represents a strategic pivot toward 'medical necessity' in federal drug policy. By accelerating research into psychedelics, the U.S. government is acknowledging that existing mental-health treatments may be insufficient, potentially paving the way for future FDA approvals of psychedelic-assisted therapies.
